Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia

por Sive, J I, Basilico, S, Hannah, R, Kinston, S J, Calero-Nieto, F J, Göttgens, B
Publicado 2016

Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia

por Oram, S H, Thoms, J, Sive, J I, Calero-Nieto, F J, Kinston, S J, Schütte, J, Knezevic, K, Lock, R B, Pimanda, J E, Göttgens, B
Publicado 2013

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

por Chin, M, Sive, J I, Allen, C, Roddie, C, Chavda, S J, Smith, D, Blombery, P, Jones, K, Ryland, G L, Popat, R, Rismani, A, D'Sa, S, Rabin, N, Gale, R E, Yong, K L
Publicado 2017

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS

por Khwaja, J., Bomsztyk, J., Mahmood, S., Wisniowski, B., Shah, R., Tailor, A., Yong, K., Popat, R., Rabin, N., Kyriakou, C., Sive, J., Worthington, S., Hart, A., Dowling, E., Correia, N., Bygrave, C., Rydzewski, A., Jamroziak, K., Wechalekar, A.
Publicado 2022